Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Merkel Cell Carcinoma Pipeline Drugs Development Market Report Overview

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Symptom includes painless nodule on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery

The Merkel Cell Carcinoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.

Merkel Cell Carcinoma Pipeline Drugs Market - Competitive Landscape

A few of the leading companies in the Merkel Cell Carcinoma pipeline drugs market are Bristol-Myers Squibb Co, Aulos Bioscience Inc, F. Hoffmann-La Roche Ltd, ImmunityBio Inc, and others.

Bristol-Myers Squibb Co: Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals, and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Companies

Buy the Full Report for More Competitor Insights into the Merkel Cell Carcinoma Pipeline Drugs Market, Download a Free Report Sample

Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Targets

The key targets in the Merkel Cell Carcinoma pipeline drugs market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cytotoxic T Lymphocyte Protein 4, E3 Ubiquitin Protein Ligase Mdm2, and Others. Programmed Cell Death Protein 1 has the highest number of products in development in the Merkel Cell Carcinoma pipeline drugs market.

Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Targets

Buy the Full Report for More Target Insights into the Merkel Cell Carcinoma Pipeline Drugs Market, Download a Free Report Sample

Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Merkel Cell Carcinoma pipeline drugs market Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic T Lymphocyte Protein 4 Antagonist, E3 Ubiquitin Protein Ligase Mdm2 Inhibitor, and Others. Programmed Cell Death Protein 1 Antagonist leads the Merkel Cell Carcinoma pipeline drugs market in terms of MoA.

Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Mechanisms of Action

Buy the Full Report for More MoA Insights into the Merkel Cell Carcinoma Pipeline Drugs Market, Download a Free Report Sample

Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Merkel Cell Carcinoma pipeline drugs market are intravenous, intratumor, subcutaneous, oral, and others. The intravenous RoA has the highest number of Merkel Cell Carcinoma drugs in development in 2022.

Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Routes of Administration

Buy the Full Report for More RoA Insights into the Merkel Cell Carcinoma Pipeline Drugs Market, Download a Free Report Sample

Merkel Cell Carcinoma Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Merkel Cell Carcinoma pipeline drugs market are monoclonal antibody, small molecule, fusion protein, oncolytic virus, and others. Monoclonal antibody leads the Merkel Cell Carcinoma pipeline drugs market in terms of molecule type.

Merkel Cell Carcinoma Pipeline Drugs Market Analysis by Molecule Types

Buy the Full Report for More Molecule Type Insights into the Merkel Cell Carcinoma Pipeline Drugs Market, Download a Free Report Sample

Merkel Cell Carcinoma Pipeline Drugs Market – Featured News and Press Releases

• On Nov 08, 2022, Immunomic Therapeutics receives FDA fast track designation for ITI-3000, a pDNA vaccine, in development for the treatment of Merkel cell carcinoma.
• On Jul 21, 2022, Immunomic doses first subject in Phase I Merkel cell carcinoma vaccine trial.

Merkel Cell Carcinoma Pipeline Drugs Target Outlook, 2022

• Programmed Cell Death Protein 1
• Programmed Cell Death 1 Ligand 1
• Cytotoxic T Lymphocyte Protein 4
• E3 Ubiquitin Protein Ligase Mdm2
• Others

Merkel Cell Carcinoma Pipeline Drugs MoA Outlook, 2022

• Programmed Cell Death Protein 1 Antagonist
• Programmed Cell Death 1 Ligand 1 Inhibitor
• Cytotoxic T Lymphocyte Protein 4 Antagonist
• E3 Ubiquitin Protein Ligase Mdm2 Inhibitor
• Others

Merkel Cell Carcinoma Pipeline Drugs RoA Outlook, 2022

• Intravenous
• Intratumor
• Subcutaneous
• Oral
• Others

Merkel Cell Carcinoma Pipeline Drugs Molecule Type Outlook,2022

• Monoclonal Antibody
• Small Molecule
• Fusion Protein
• Oncolytic Virus
• Others

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma.
• The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Merkel Cell Carcinoma therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Merkel Cell Carcinoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Merkel Cell Carcinoma

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Merkel Cell Carcinoma pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.